Insmed (INSM)
(Delayed Data from NSDQ)
$24.80 USD
-0.12 (-0.48%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $24.50 -0.30 (-1.21%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
INSM 24.80 -0.12(-0.48%)
Will INSM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for INSM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INSM
Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
INSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
Amgen (AMGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know
Other News for INSM
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Roblox upgraded, Qualcomm initiated: Wall Street's top analyst calls
Roblox upgraded, Qualcomm initiated: Wall Street's top analyst calls
Analysts Conflicted on These Healthcare Names: Cartesian Therapeutics (RNAC), Insmed (INSM) and BioNTech SE (BNTX)